Kornimate/medical-research-clean huggingface dataset:
speckle tracking and inhaled nitric oxide in acute respiratory distress syndrome

Conditions: ARDS; Right Ventricle

Summary: acute cor pulmonale is one of deadly complications of mechanically ventilated acute respiratory distress syndrome (ards), which can lead to right ventricular dysfunction and worsen the hemodynamics of the patient. for several years, transthoracic (tte) and transesophageal echocardiography (tee) have replaced the pulmonary artery catheter to monitor cardiac function reliably and non-invasively. speckle tracking is an echocardiographic technique that allows a two-dimensional strain (2d) analysis of right ventricular systolic function. right ventricular global strain (rvgls) is a strain parameter, allowing an early and more accurate diagnosis of right ventricular dysfunction than conventional parameters. this project will consist of performing tte and tee measurements at h0, 30min, h1, h2, and h24 after ino administration in patient with ards under mechanical ventilation. the patient will be declared responder to ino, if there is an increase of more than 20% of the pao2/fio2. 30 minutes after a dose of 10ppm of ino.


Eligibility criteria:
inclusion criteria: * adult patient (age \> 18 years) * hospitalized in the intensive care and post-operative care unit of the amiens-picardie university hospital * patient with ards (defined by the berlin criteria) requiring mechanical ventilation with a p/f ratio \< 200 and requiring ino * beneficiary of social security * signature of the consent to participate in the study by the patient or, if unconscious, his legal representative/next of kin exclusion criteria: * pregnant or breastfeeding woman * contraindications to tee (major upper gastro-intestinal surgery, mediastinal radiotherapy, active esophagitis, esophageal varices) * contraindications to the placement of an esophageal probe (recent upper gastro-intestinal surgery, active ulcer, active esophagitis) * presence of atrial fibrillation on echocardiographic examinations * contraindications to the administration of ino * patients with chronic treatment allowing pulmonary arterial vasodilatation by sildenafil.

Keywords: speckle tracking ards right ventricle ino strain
stiripentol in dravet syndrome

Conditions: Dravet Syndrome

Summary: the patient has failed all other available agents and has intractable epilepsy due to dravet syndrome. stiripentol is highly efficacious in dravet syndrome. the overall goals of therapy with stiripentol are primarily to significantly reduce the frequency and severity of seizures.


Eligibility criteria:
inclusion criteria: * genetic diagnosis of dravet syndrome with intractable seizures despite failing all available medications for seizures

Keywords: treatment with stiripentol
testing fish oil derivatives in healing of chronic venous leg ulcers

Conditions: Venous Stasis Ulcers

Summary: the purpose of this study is to test the efficacy of an oral, nutrient intervention containing the bioactive components of fish oil to promote healing of chronic venous leg ulcers (cvlu). if this systemic, nutrient intervention is found to alter the microenvironment of cvlu, the science of wound healing and care of patients with cvlu will be vastly improved.

the pathogenesis of cvlu involves high numbers of activated polymorphonuclear leukocytes (pmn) that are associated with persistent inflammation in the wound bed 5-9. we propose to test the efficacy of an oral, nutrient intervention containing the bioactive components of fish oil to assuage pmn activity and promote healing of cvlu. if this systemic, nutrient intervention is found to alter the microenvironment of cvlu, the science of wound healing and care of patients with cvlu will be vastly improved. the purpose of this study is to test three fundamental corollaries of our organizing hypothesis in a 2-group, double-blind, randomized, experimental design on cvlu patients. the findings from the proposed experiments will increase our understanding of lipid mediators that influence wound healing and pmn function, and may lead to an innovative approach to reduce the physical and emotional burdens of nonhealing or recurrent cvlu.

Eligibility criteria:
inclusion criteria: * men and women * ages 18-85 years * having at least one existing cvlu between the ankle and knee for ≥ 3 months * medical clearance to take 81mg/d of aspirin * prescribed compression therapy; ambulatory * ankle brachial pressure index (abpi) of ≥ 0.8 * target wound of ≥ 1 x 1 inches (6.25 cm2) * can understand english and sign own consent exclusion criteria: * allergy to fish or seafood * exposed bone, tendon or fascia around target wound * receiving warfarin or plavix therapy * immunologic related condition (e.g. crohn's disease, systemic lupus erythematosus) * chronic inflammatory skin diseases (e.g. pyoderma gangrenosum, psoriasis) * requiring non-steroidal anti-inflammatory drugs \> 2x a week * nutritional supplements or corticosteroids * chronic renal insufficiency * already in a study related to cvlu.

Keywords: leg ulcers wounds fish oil lipid mediators chronic venous stasis ulcers
cesarean scar pregnancy and clinical outcomes

Conditions: Blood Loss; Repeat Cesarean Section; Maternal Transmission; Hysterectomy; Placenta Accreta Spectrum; Abortion

Summary: this study is a prospective cohort study, led by prof. zhao yangyu, from the department of gynecology \& obstetrics, peking university third hospital.

cesarean section, myomectomy and other surgeries for uterus are likely to cause scars in different parts of the uterus. during the subsequent pregnancy, the incidence rate of cesarean scar pregnancy, placenta previa, placenta increta and the risk of termination of the first and mid-trimester pregnancy is likely to increase. cesarean scar pregnancy is regarded as a risk factor of uterine rupture in the third trimester of pregnancy or delivery period, which severely affects the maternal and perinatal health and safety. this study is planning to prospectively include pregnant women aged 20-49 years from peking university third hospital. all women with diagnosis on cesarean scar pregnancy was included prior to 14 wks of gestation. we divided the women into three different groups: type i, type ii and type iii according to characteristics in gestation sac,uterine scar, bladder, the latter with potentially worse outcomes in term of maternal morbidity and mortality. data including demographics, medical history, reproductive history, prenatal health care, gestational complications, and pregnancy and birth outcomes will be collected via electronic data capture system.

Eligibility criteria:
inclusion criteria: * female aged ≥ 20 years * female with cesarean scar pregnancy * less than 14 gestational weeks * planning to receive prenatal healthcare and delivery service at the study hospital exclusion criteria: * inability to provide informed consent * women with mental disorders
registry on real-life experience with left atrial appendage occlusion

Conditions: Atrial Fibrillation

Summary: the objective of this observational non-randomized multicenter study is to compile real-world clinical characteristics and outcomes data for patients treated with laa (left atrial appendage) closure systems in a daily clinical setting.


Eligibility criteria:
inclusion criteria: * patients who are eligible for a laa occlusion device and treated with a commercially available device according to international and local guidelines and per physician discretion. exclusion criteria: * none

Keywords: atrial fibrillation stroke thrombus left atrial appendage bleeding
fecal filtrate as a treatment option of multiple recurrent clostridioides difficile infection

Conditions: Clostridium Difficile Infection; Recurrent Clostridium Difficile Infection

Summary: clostridioides difficile infection (cdi) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%). the treatment of cdi, especially the recurrent form of the disease is still considered a challenge. the filtrate randomized controlled trial aims to investigate the safety and efficacy of fecal filtrate transplantation in the treatment of recurrent cdi and compare it with conventional fecal microbiota transplantation (fmt).

the treatment of recurrent cdi is still a burden on the healthcare system. fmt is highly effective for the treatment of recurrent cdi, resulting in the resolution of cdi up to 100% of the cases. fmt also has a good short-term safety profile, however long-term events like transfer of multiresistant bacteria and other living microorganism is still a major problem. on the other hand, the fecal filtrate contains only bacterial debris, proteins, and antimicrobial compounds and not intact microorganisms. the filtrate trial is a multicenter, two-arm randomized controlled trial, and aims to compare the safety and efficacy of fecal filtrate transplantation to conventional fecal microbiota transplantation (fmt) in the treatment of recurrent cdi. adult patients with multiple recurrent (\>1) cdis will be randomized 1:1 to receive either fmt or fecal filtrate transplantation. the transplantation will be carried out using lyophilized capsule on each arm. the primary endpoint of the study will be the clinical resolution of cdi-associated diarrhea 8 weeks after the interventions. questionnaires will be completed on enrollment and at the time of each follow-up. adverse events will be recorded and reported to the relevant institutional and national ethics committee. after the intervention, a one-year follow-up is also planned. blood and stool samples will be collected at baseline and at each follow-up.

Eligibility criteria:
inclusion criteria: * age ≥18 years * multiple recurrent cdi (≥2 previous episodes of cdi) * at least 3 or more loose or watery stools (bristol 5-7) per day * a positive glutamate dehydrogenase (gdh)-enzyme and positive cdi toxin a and/or b test * the patient or the legal guardian sign the written informed consent exclusion criteria: * pregnancy or breastfeeding * ongoing antibiotic treatment * fulminant cdi * previous fmt * immunodeficiency * need of intensive care * requirement for vasoactive drugs * other cause of diarrhea * inflammatory bowel diseases * irritable bowel syndrome * life expectancy shorter than 3 months * unavailable for follow-up visits

Keywords: fecal microbiota transplantation fecal filtrate recurrent infection
pilot study on bp1.4979 effect on binge eating disorders

Conditions: Binge-Eating Disorder

Summary: this pilot study is to assess the efficacy and safety of bp1.4979 15 mg bid in female patients with moderate to severe binge eating disorder (bed), as defined according to dsm-5 guidelines.

first clinical study to assess the effect of the bp1.4979 on bed in female patients over an 8 week-tretament period.

Eligibility criteria:
inclusion criteria: * patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to beginning any protocol required procedures. * female aged between 18 and 65 years, inclusive. * diagnosis of bed according to dsm-5 criteria * bmi \< 50 kg/m2. exclusion criteria: * current diagnosis of bulimia nervosa or anorexia nervosa. * history of bariatric surgery. * patient who is pregnant, lactating, or of childbearing potential who is not using adequate contraceptive measures. the following are considered adequate methods of birth control: 1. intrauterine device (iud); 2. barrier protection; 3. contraceptive implantation system; 4. oral contraceptive pills; 5. surgically sterile patient; and 6. abstinence. all participants should have a negative pregnancy test prior to randomization * ongoing alcohol or tobacco addiction treatment (except nicotine replacement therapy \[nrt\] with at least one-month stable dose prior to screening visit).
research on excessive iodine status in pregnancy

Conditions: Excessive Iodine Status; Thyroid Dysfunction, Antepartum; Pregnancy Related; Neonatal Disorder

Summary: to explore main cause and health impact of iodine excess during pregnancy, we performed iodine evaluation for 390 consecutive pregnant women from january 1st, 2016 to december 31st, 2016. among them, 18 women (4.62%) with apparently elevated urinary iodine concentration (uic) were enrolled onto this study for subsequent follow-up. history of high iodine exposure was collected from all participants. parameters about iodine status were monitors until termination of pregnancy, and dietary iodine intake condition and thyroid function were also evaluated.

a prospective follow-up was arranged for the 18 pregnant women with excessive iodine status. history of iodine exposure (including hysterosalpingography (hsg) using an oil-soluble iodinated contrast medium, examination by computed tomography scan with contrast, administration of amiodarone, history of receiving radioiodine therapy, etc.) was collected from all participants. evaluation of dietary iodine intake was performed through a 72-hour dietary recall.the serum iodine concentration (sic) and urinary iodine concentration (uic) were monitored continuously in the whole course of pregnancy. all subjects with excessive iodine load were recommended by nutritionists to have their dietary iodine intake restricted, and resume iodine-containing supplements and foods until the uic\<250 μg/l and sic≤90 μg/l. after delivery, maternal colostrum iodine concentration and neonatal iodine status (including neonatal uic, condition of congenital hypothyroidism screening tests, and thyroid physical examination) were also assessed.

Eligibility criteria:
inclusion criteria: * pregnant women with apparently elevated urinary iodine concentration (uic ≥250μg/l) and serum iodine concentration (sic\>90μg/l) were enrolled in this study. exclusion criteria: * subject who did not sign the informed consent or whose clinical date was not intact was excluded in our study.

Keywords: iodine excess cause pregnancy urinary iodine concentration serum iodine concentration breast milk iodine concentration
study of nasal irrigation versus nasal spray for chronic nasal and sinus symptoms

Conditions: Chronic Rhinosinusitis

Summary: this study will compare nasal saline irrigation with nasal saline spray for the treatment of chronic nasal and sinus symptoms. participants will complete a questionnaire regarding their nasal and sinus symptoms and will be randomly assigned to one of the treatment groups. each participant will be instructed on how to perform daily nasal treatment.the subjects will complete follow-up surveys at regular intervals to assess any change in their nasal symptoms after starting nasal saline treatment. participants may take their usual medications for sinus symptoms during their participation in the study.

see publication: arch otolaryngolheadnecksurg. 2007;133(11):1115-1120

Eligibility criteria:
inclusion criteria: * age \> 18 years * presence of any one of the following symptoms for \> 4 days/week and \> 15 days in the past 1 month: * nasal stuffiness * nasal congestion * nasal dryness or crusting * abnormal nasal discharge * thick nasal discharge exclusion criteria: * functional endoscopic sinus surgery (fess) in the last 3 months * epistaxis in the last 3 months that required treatment * acute illness like otitis media, laryngitis, pharyngitis, or rhinitis in the last 2 weeks * acute attack of asthma or bronchitis in the last 2 weeks * inability to speak or read english * current use of any of the study medications regularly for more than a week in the last 1 month * any history of intolerance to saline treatment (if used)

Keywords: chronic nasal sinus symptoms
the anti-inflammatory effects of harkány medicinal water

Conditions: Rheumatoid Arthritis; Psoriasis

Summary: the study aims to provide evidence on the effectiveness of harkány medicinal water in psoriatic and rheumatoid arthritis patients using subjective and objective methods. it is a cross-over study, so first half of patients will receive medicinal water, the other half will receive tap water treatment, and after 6 months treatments will be repeated, but patients will receive the other type of water.

several studies have shown that medicinal waters are highly effective in the treatment of many diseases. existing clinical trials were unable to provide scientific evidence by using the highest international standards to justify the efficiency of thermal waters. harkány medicinal water has been used for rheumatic, skin and locomotor diseases for more than 100 years. its beneficial effects are indisputable. however, to introduce these effects, internationally high-level scientific methods and investigations are needed. psoriasis is among the most common dermatological diseases worldwide. its significance is emphasized by adverse effects on quality of life, caused by chronic pain, physical and psychical disability due to psoriatic plaques. former studies revealed an increased risk of inflammatory bowel disease, cardiovascular disease and certain types of cancer. moreover, excessive oxidative stress can be responsible for the onset of psoriasis complications. rheumatoid arthritis (ra) is an autoimmune disease responsible for significant morbidity, characterized by articular inflammation. oxidative stress is a key marker for determining pathophysiology of patients with ra. the pathophysiological link between these conditions is the presence of excessive oxidative stress. subjective methods will include questionnaires, objective markers of disease severity will include the measurement of biomarkers from blood samples.

Eligibility criteria:
inclusion criteria: * signed consent statement * over 18 years of age * lack of underlying renal disease (gfr \>60 ml/min/1.73m2) * lack of severe inflammation (wbc \<20.000 g/l; crp \<50 mg/l; we \<40 mm/h) * psoriasis vulgaris with skin lesions * mild and inactive ra exclusion criteria: * having received any kind of balneotherapy within 1 year before admission * discontinuance of rehabilitation * withdrawal of consent * clinically significant difference in severity of the patient's condition on 1st or 2nd admission * severe ra * patients suffering from cancer * patients suffering from inflammatory bowel disease * patients underwent stroke within 1 year * severe hypercholesterolemia * severe diabetes * patients with renal insufficiency * patients receiving any kind biological therapy * patients whose medication has changed during the study period or one month prior to the second treatment session

Keywords: medicinal water,inflammation,biomarker,inflammatory disease
importance of the infusion rate for the plasma expanding effect of 5% albumin in the septic patient

Conditions: Sepsis

Summary: correction of hypovolemia is an important therapeutic measure，even though there is no consensus regarding infusion rates, a plasma volume (pv) expander is often given at a fast rate to treat a suspected hypovolemia without delay which can be associated with aggravation of adverse interstitial accumulation of macromolecules and fluid, especially in inflammatory conditions such as sepsis.the smallest possible volumes for pv resuscitation to maintain normovolemia should be used to reduce the risk of simultaneous interstitial fluid accumulation. the investigators tested the hypothesis that a slow infusion rate of a pv expander results in better plasma expansion than a fast infusion rate to patients with severe sepsis or septic shock.


Eligibility criteria:
inclusion criteria: * admitted to the icu patients with severe sepsis or septic shock (diagnosis according to the 2012 surviving sepsis campaign guidelines) * there is low blood pressure (sbp \< 90 or mean arterial pressure(map) \< 65 or the systolic blood pressure is decreased 40 mmhg more than the basic level) or lactic acid or greater for 4 mmol/l * the informed consent exclusion criteria: * less than 18 years of age * more than 80 years old * pregnant women * albumin allergies * the dying patients expected lifetime no more than 24 hours) * patient with myocardial infarction, heart failure * liver failure * refused to sign the informed consent

Keywords: albumin
chemotherapy followed by radiation therapy in treating adults with supratentorial glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining radiation therapy with chemotherapy may kill more tumor cells. purpose: phase ii trial to study the effectiveness of procarbazine, lomustine, and vincristine followed by radiation therapy in treating adults who have supratentorial glioma.

objectives: i. estimate the response rate of patients with newly diagnosed supratentorial low-grade glioma following neoadjuvant chemotherapy with pcv (procarbazine/lomustine/vincristine). ii. describe the toxicity of pcv. iii. determine the incidence of disease progression in these patients during pcv treatment. outline: the following acronyms are used: ccnu lomustine, nsc-79037 pcb procarbazine, nsc-77213 pcv pcb/ccnu/vcr vcr vincristine, nsc-67574 3-drug combination chemotherapy followed by radiotherapy. pcv; followed by external-beam cranial irradiation using at least 6 mv photons.

Eligibility criteria:
disease characteristics: histologically confirmed supratentorial \* grade i/ii glioma, including: diffuse fibrillary astrocytoma no pilocytic astrocytoma no mixed tumor with ependymoma elements \* supratentorial sites include: frontal, temporal, parietal, or occipital lobes thalamus, basal ganglia, or midbrain lateral or third ventricles pons, medulla, or optic chiasm tumors allowed only if secondary to eligible tumor more than 1 separate tumor allowed diagnosis based on surgical biopsy or subtotal resection measurable or evaluable disease on t2-weighted mri required patient characteristics: age: 18 and over performance status: ecog 0-2 hematopoietic: wbc greater than 3,500/mm3 platelet count greater than 130,000/mm3 hemoglobin greater than 9 g/dl hepatic: bilirubin less than 2 times upper limit of normal (uln) ast less than 2 times uln alkaline phosphatase less than 2 times uln renal: creatinine less than 1.5 times uln other: no active or uncontrolled infection no second malignancy within 3 years except: nonmelanomatous skin cancer in situ cervical cancer no pregnant or nursing women negative pregnancy test required within 7 days prior to entry effective contraception required of fertile patients prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: at least 1 week since prior steroids or stable steroid dose for at least 1 week prior to study radiotherapy: no prior cranial or head and neck irradiation surgery: see disease characteristics

Keywords: adult diffuse astrocytoma